Sign in Sign up for free

Last updated: 29 August 2024 at 4:45pm EST

Seth Fischer Net Worth




The estimated Net Worth of Seth H. Z. Fischer is at least $232 Thousand dollars as of 6 February 2023. Mr. Fischer owns over 1,018 units of Marinus Pharmaceuticals Inc stock worth over $8,376 and over the last 11 years he sold MRNS stock worth over $62,049. In addition, he makes $161,200 as Independent Director at Marinus Pharmaceuticals Inc.

Mr. Fischer MRNS stock SEC Form 4 insiders trading

Seth has made over 4 trades of the Marinus Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 1,018 units of MRNS stock worth $6,658 on 6 February 2023.

The largest trade he's ever made was selling 12,000 units of Marinus Pharmaceuticals Inc stock on 17 June 2021 worth over $50,880. On average, Seth trades about 519 units every 77 days since 2013. As of 6 February 2023 he still owns at least 6,026 units of Marinus Pharmaceuticals Inc stock.

You can see the complete history of Mr. Fischer stock trades at the bottom of the page.





Seth Fischer biography

Seth H. Z. Fischer serves as Independent Director of the Company. He has served on our Board since September 2016. Mr. Fischer is currently CEO and Director of VIVUS, Inc., a publicly traded biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. Prior to VIVUS, Mr. Fischer served in various positions at Johnson & Johnson, most recently as Company Group Chairman, Johnson & Johnson and Worldwide Franchise Chairman of Cordis Corporation. Prior to that he served as Company Group Chairman, North America Pharmaceuticals, which included responsibilities for Ortho-McNeil Pharmaceuticals, Janssen and Scios and prior to that, Mr. Fischer served as President of Ortho-McNeil Pharmaceuticals. Mr. Fischer’s operating responsibilities encompassed the commercialization of products in multiple therapeutic categories including Topamax® for epilepsy and migraines and products in the neurologic, analgesic, anti-infective, cardiovascular, psychiatric and women’s health areas. He is a member of the Boards of Directors of Agile Therapeutics, Inc. and BioSig Technologies, Inc., and an advisor to MedHab, LLC. Mr. Fischer earned a bachelor’s degree in general studies from Ohio University and served as a captain in the U.S. Air Force.

What is the salary of Seth Fischer?

As the Independent Director of Marinus Pharmaceuticals Inc, the total compensation of Seth Fischer at Marinus Pharmaceuticals Inc is $161,200. There are 10 executives at Marinus Pharmaceuticals Inc getting paid more, with Scott Braunstein having the highest compensation of $2,245,680.



How old is Seth Fischer?

Seth Fischer is 64, he's been the Independent Director of Marinus Pharmaceuticals Inc since 2016. There are 2 older and 10 younger executives at Marinus Pharmaceuticals Inc. The oldest executive at Marinus Pharmaceuticals Inc is Martha E. Manning, 66, who is the VP, Gen. Counsel & Sec..

What's Seth Fischer's mailing address?

Seth's mailing address filed with the SEC is C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, A8, H4M 2X6.

Insiders trading at Marinus Pharmaceuticals Inc

Over the last 10 years, insiders at Marinus Pharmaceuticals Inc have traded over $13,562,679 worth of Marinus Pharmaceuticals Inc stock and bought 2,520,427 units worth $19,488,416 . The most active insiders traders include Nicole Vitullo, Capital Life Sciences Inves..., and Anand Mehra. On average, Marinus Pharmaceuticals Inc executives and independent directors trade stock every 68 days with the average trade being worth of $149,293. The most recent stock trade was executed by Christina Shafer on 5 August 2024, trading 3,820 units of MRNS stock currently worth $4,355.



What does Marinus Pharmaceuticals Inc do?

marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides



What does Marinus Pharmaceuticals Inc's logo look like?

Marinus Pharmaceuticals Inc logo

Complete history of Mr. Fischer stock trades at Agile Therapeutics Inc, Esperion Therapeutics, Marinus Pharmaceuticals Inc, Spectrum Pharmaceuticals, VIVUS, Biosig Technologies Inc, and Milestone Pharmaceuticals Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
6 Feb 2023 MRNS Marinus Pharmaceuticals Inc Seth H. Z. Fischer
Sale 1,018 $6.54 $6,658
6 Feb 2023
6,026 ↗
21 Jun 2022 SPPI Spectrum Pharmaceuticals, Inc. Seth H. Z. Fischer
Director
 Sale 5,711 $0.79 $4,512
21 Jun 2022
29,066 ↗
17 Jun 2021 SPPI Spectrum Pharmaceuticals, Inc. Seth H. Z. Fischer
Director
 Sale 12,000 $4.24 $50,880
17 Jun 2021
34,777 ↗
11 Mar 2014 VVUS VIVUS, Inc. Seth H. Z. Fischer
Chief Executive Officer
 Buy 3,080 $6.07 $18,696
11 Mar 2014
3,080 ↗


Marinus Pharmaceuticals Inc executives and stock owners

Marinus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: